A Study to Evaluate ctDNA Diagnostics in Recurrent Breast Cancer Patients

Overview

About this study

The purpose of this study is to to establish a minimally-invasive blood based test for the detection of clinically actionable genetic changes in breast cancer patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18 years or older.
  • Histologic evidence of breast cancer with known hormone receptor and HER2 status.
  • Initiation of new systemic therapy for recurrent or progressive metastatic disease or unresectable locally recurrent disease within four weeks of the blood draw.
  • An understanding of the protocol and its requirements, risks, and discomforts.
  • The ability and willingness to sign an informed consent.

Exclusion Criteria:

  • Pregnancy or lactation (for females).
  • Inability on the part of the patient to understand the informed consent or be compliant with the protocol.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Minetta Liu, M.D.

Open for enrollment

Contact information:

Katlyn Hanson

(507) 284-3988

Hanson.Katlyn@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20518197

Mayo Clinic Footer